Lindsey Shapiro, PhD,  science writer—

Relapsing-remitting multiple sclerosis (RRMS) patients with low educational attainment are more likely to delay the start of disease-modifying therapies (DMTs) after a diagnosis than those with a high educational status, a Danish study suggests. Educational status wasn’t significantly associated with diagnostic delays after the onset of symptoms,…

A three-month course of acupuncture was associated with gains in certain aspects of cognition for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial. The traditional Chinese medicine was also linked to less fatigue, improved sleep, and reductions in certain psychological problems such as depression. The findings…

A 14-week regimen of physical therapy combined with PoNS — a neurostimulator device used to improve mobility — led to significant gait improvements in people with multiple sclerosis (MS), with evidence that its benefits are sustained over time, according to new data from the real-world PoNSTEP clinical study.

Immunic Therapeutics says it remains “on track” in testing its multiple sclerosis treatment candidate vidofludimus calcium in twin Phase 3 clinical trials with people who have relapsing disease — and in the Phase 2 CALLIPER study involving those with progressive forms of MS. Indeed, in a new company…

An interplay between genetic and environmental risk factors, including tobacco smoke exposure, affects brain development in early childhood, which could increase the likelihood a person will develop multiple sclerosis (MS), according to a recent study. Among young children in the Netherlands, being at a high genetic risk for MS,…

Blood levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage used in multiple sclerosis (MS) research — are influenced by factors such as age, body mass index (BMI), and storage conditions of the blood samples, according to a recent report. Such factors may need to…

Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates being developed for multiple sclerosis (MS) and other diseases. Poseida and Roche have been collaborating since 2022 on cell therapies for people with blood cancer. The companies…

Activation of a protein called DLK may drive the death of nerve cells that have been demyelinated, or lost their protective myelin coating, in multiple sclerosis (MS), according to a new study from U.S. researchers. The findings shed light on how a failure to repair lost or damaged…

The number of people living with multiple sclerosis (MS) in Australia rose by more than 50% in the decade between 2010 and 2021, according to a recent report. These findings are consistent with global observations that the prevalence of MS has been steadily increasing worldwide. “Research and rapidly translated…

An independent data monitoring committee has recommended that the twin ENSURE Phase 3 trials testing vidofludimus calcium in people with relapsing forms of multiple sclerosis (MS) continue as planned without adjustments. The opinion that the trials are worth continuing was based on a review of interim, unblinded trial…

Helius Medical Technologies is opposing new decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that stipulate how much of the cost of its PoNS device — a neurostimulator designed to improve mobility in people with multiple sclerosis (MS) — will be covered by these…

Transplanting genetically engineered oligodendrocyte progenitor cells (OPCs), which give rise to mature myelin-making cells, significantly boosted myelin repair in mice with multiple sclerosis (MS)-like chronic brain lesions. The cells were engineered to ignore chemical signals that would normally inhibit OPCs being recruited into lesions and then restore…

Sanofi has ended a Phase 2 clinical trial into oditrasertib, an investigational RIPK1 inhibitor therapy, in people with relapsing and progressive multiple sclerosis (MS) after it failed to meet its goals. The study, which had started dosing early last year, failed to show that oditrasertib significantly lowered…

Combining the approved medication Tecfidera (dimethyl fumarate) with targeted therapy using a patient’s own immune cells may eventually be a promising way of treating multiple sclerosis (MS), according to recent research. The targeted therapy uses tolerogenic dendritic cells (tolDCs), which are being tested in clinical trials, to make…

By studying pairs of identical twins, researchers have identified a population of immune cells whose early activation and migration into the brain might contribute to multiple sclerosis (MS) onset. MS patients showed an altered profile of a population of immune cells called CD8 T-cells in the blood relative to…

Acupuncture may be a promising complementary approach for easing fatigue and improving quality of life for people with multiple sclerosis (MS), according to a small review study and meta-analysis. Still, the study highlighted a need for future clinical trials that use more standardized acupuncture approaches, according to the researchers,…

Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with nonrelapsing secondary progressive multiple sclerosis (SPMS), according to new data from the HERCULES Phase 3 clinical trial. The investigational BTK inhibitor also was found to significantly…

Continuous treatment with Briumvi (ublituximab) over five years was associated with low rates of relapses and confirmed disability progression among people with relapsing forms of multiple sclerosis (MS), according to analyses from the open-label extension (OLE) phase of the treatment’s ULTIMATE Phase 3 trials. Relative to patients who…

The pharmaceutical company Médunik Canada and Population Council, a nonprofit research organization, are teaming up to investigate the potential use of segesterone acetate, a derivative of the hormone progesterone, as a multiple sclerosis (MS) therapy. The compound is expected to promote the restoration of myelin, the…

A clinical trial is evaluating whether combining a cognitive rehabilitation program with a virtual reality (VR)-based aerobic exercise regimen will improve learning and memory in people with multiple sclerosis (MS) and motor disability. Researchers expect the approach will show cognitive benefits via positive effects on a brain region called…

A year of treatment with the experimental BTK inhibitor fenebrutinib was safe and nearly entirely suppressed signs of disease activity, including relapses, disability progression, and brain lesions, in people with relapsing forms of multiple sclerosis (MS), according to new data from the open-label extension part of a Phase…

Researchers uncovered a mechanism by which regulatory T-cells (Tregs), immune cells that keep the immune system in check and prevent its overactivity, become dysfunctional in people with multiple sclerosis (MS) and other autoimmune conditions. Tregs from MS patients exhibited increased levels of a protein called PRDM1-S that ultimately caused…

Obesity promotes molecular signatures associated with more inflammation and multiple sclerosis (MS) signaling pathways specifically in females, which may explain the link between obesity and a higher risk of MS in women. These are the findings of a new study analyzing data not only from obese and non-obese women…

About a third of people with relapsing-remitting multiple sclerosis (RRMS) exhibit cognitive impairments, according to a review by Australian researchers of 50 previously published studies. The findings suggest that cognitive issues might be somewhat less common in RRMS than previous reports have indicated, with prior estimates ranging from approximately…

Multiple sclerosis (MS) patients exhibited greater resistance to the effects of insulin — the hormone responsible for keeping the body’s blood sugar levels within a healthy range — and had higher overall insulin levels compared with people without the neurodegenerative disease, a meta-analysis of published studies found. These findings…

Measures associated with how well individuals can modulate their backward walking speed could be used as a screening tool for mobility and cognition problems in people with multiple sclerosis (MS), according to a study by Michigan researchers. A diminished ability to alter walking speed on demand correlated with worse…

Researchers have identified characteristics of regulatory T-cells (Tregs) — a family of immune cells that help keep harmful immune reactions in check — that could make it easier to develop targeted treatments for autoimmune conditions like multiple sclerosis (MS). They found that Tregs exist as a common pool that…

A three month cognitive rehabilitation program, with or without aerobic exercise, increased tissue volume and activity in brain regions linked to cognition among people with progressive forms of multiple sclerosis (MS), clinical trial data suggests. The MRI findings offer potential biological explanations about why cognitive rehabilitation leads to cognitive…

England’s National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of Mavenclad (cladribine) in people with aggressive relapsing-remitting multiple sclerosis (RRMS) in ways that should help eligible patients be able to access the medication sooner. The new guidelines have less stringent…

A large clinical trial to test online programs for treating fatigue in people with multiple sclerosis (MS) will launch in the U.S. in the coming months. The study — the largest of its kind — will be funded by a nearly $4.5-million grant from the U.S. Department of…